Britton A M, Nichols J D, Draper P R
Reckitt and Colman Pharmaceuticals, Kingston-Upon-Hull, UK.
J Pharm Pharmacol. 1991 Feb;43(2):122-3. doi: 10.1111/j.2042-7158.1991.tb06646.x.
The comparative bioavailability of cimetidine in cimetidine-alginate combinations has been investigated in twelve healthy volunteers in an open crossover study. Each volunteer received a single oral dose of a commercially available alginate-cimetidine combination tablet (Algitec) or cimetidine tablets (Tagamet), co-administered with a commercially available alginate reflux suppressant liquid or tablet (Gaviscon). No significant differences were observed between treatments for Cmax, tmax, AUC0-12 or AUC0- infinity. The study demonstrated equivalent bioavailability of cimetidine when administered separately with alginate products and as a fixed dose combination product.
在一项开放性交叉研究中，对12名健康志愿者研究了西咪替丁-海藻酸盐组合中西咪替丁的相对生物利用度。每位志愿者接受单剂口服市售海藻酸西咪替丁组合片（Algitec）或西咪替丁片（泰胃美），并与市售海藻酸反流抑制剂液剂或片剂（盖胃平）共同给药。各治疗组之间在Cmax、tmax、AUC0-12或AUC0-∞方面未观察到显著差异。该研究表明，西咪替丁与海藻酸盐产品分开给药和作为固定剂量组合产品给药时生物利用度相当。
